AR062399A1 - Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de enfermedades de reaccion a tejido - Google Patents

Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de enfermedades de reaccion a tejido

Info

Publication number
AR062399A1
AR062399A1 ARP070103643A ARP070103643A AR062399A1 AR 062399 A1 AR062399 A1 AR 062399A1 AR P070103643 A ARP070103643 A AR P070103643A AR P070103643 A ARP070103643 A AR P070103643A AR 062399 A1 AR062399 A1 AR 062399A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
compound
group
treatment
Prior art date
Application number
ARP070103643A
Other languages
English (en)
Inventor
Gallego Guillermo Gimenez
Frutos Javier Angulo
De Tejada Gorman Inigo Saenz
Sanchez Pedro Cuevas
Lopez Serafin Valverde
Garrido Antonio Romero
Puerto Rosa Maria Lozano
Lopez Luis Ignacio Rivas
Nuncio Francisco Javier Moreno
Jaen Tomas Fernando Fernandez
Original Assignee
Action Medicines Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200602217A external-priority patent/ES2315117B1/es
Application filed by Action Medicines Sl filed Critical Action Medicines Sl
Publication of AR062399A1 publication Critical patent/AR062399A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicacion 1: Uso de un compuesto de formula (1) o sal o solvato farmacéuticamente aceptable, isomero o profármaco del mismo en la fabricacion de un medicamento para el tratamiento y/o la profilaxis de cualquiera de las enfermedades seleccionadas del grupo constituido por hiperplasia prostática benigna, enfermedad de Barrett, asma, reparacion de musculo esquelético y tendon, enfermedad de Crohn, colitis ulcerosa y leishmaniasis, en el que en el compuesto de formula (1) R1es - (CH2)aY o -CH=CH-(CH2)pY; Y es -SO3H, -SO3-.X+, -SO3R3, -PO3H, -PO3-.X+, -PO3R3, -CO2H, -CO2-.X+ o -CO2R3; X+ es un cation orgánico o un cation inorgánico de tal modo que la carga general del compuesto sea neutra; R9 y R9' se seleccionan independientemente de -OH y -OR2; en los que cuando R9 y R9' son ambos -OR2, entonces dichos R9 y R9' pueden ser iguales o diferentes; R2 es un grupo alquilo sustituido o no sustituido, arilo sustituido o no sustituido, alquilsulfonilo sustituido o no sustituido, arilsulfonilo sustituido o no sustituido, alquilcarbonilo sustituido o no sustituido, o un grupo arilcarbonilo sustituido o no sustituido; R3 es un grupo alquilo sustituido o no sustituido o arilo sustituido o no sustituido; a es un numero seleccionado de 0, 1, 2, 3, 4, 5 y 6; p es un numero entero seleccionado de 0, 1, 2, 3, 4, 5 y 6.
ARP070103643A 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de enfermedades de reaccion a tejido AR062399A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200602217A ES2315117B1 (es) 2006-08-16 2006-08-16 Uso de derivados 2,5-dihidroxibencenicos en la preparacion de medicamentos utiles en el tratamiento de asma.
ES200701855 2007-07-02

Publications (1)

Publication Number Publication Date
AR062399A1 true AR062399A1 (es) 2008-11-05

Family

ID=38515369

Family Applications (5)

Application Number Title Priority Date Filing Date
ARP070103640A AR062396A1 (es) 2006-08-16 2007-08-16 Uso de derivados de 2,5-dihidroxibenceno para el tratamiento de enfermedades angiogenicas
ARP070103634A AR062390A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
ARP070103637A AR062393A1 (es) 2006-08-16 2007-08-16 Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor
ARP070103639A AR062395A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares
ARP070103643A AR062399A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de enfermedades de reaccion a tejido

Family Applications Before (4)

Application Number Title Priority Date Filing Date
ARP070103640A AR062396A1 (es) 2006-08-16 2007-08-16 Uso de derivados de 2,5-dihidroxibenceno para el tratamiento de enfermedades angiogenicas
ARP070103634A AR062390A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
ARP070103637A AR062393A1 (es) 2006-08-16 2007-08-16 Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor
ARP070103639A AR062395A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares

Country Status (8)

Country Link
US (2) US20080114063A1 (es)
EP (3) EP2056804B1 (es)
AR (5) AR062396A1 (es)
AT (2) ATE510536T1 (es)
CL (5) CL2007002388A1 (es)
ES (1) ES2495965T3 (es)
PT (3) PT2056804E (es)
WO (5) WO2008020033A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080125485A1 (en) 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
US20070149618A1 (en) * 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
ES2238924B1 (es) * 2004-02-17 2006-12-01 Investread Europa, S.L. Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
MX2009001660A (es) * 2006-08-16 2009-04-24 Action Medicines Sl Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
US20110196040A1 (en) 2008-02-15 2011-08-11 Action Medicines S.L. Skin Penetration Enhancing Systems for Polar Drugs
FR2951085B1 (fr) * 2009-10-09 2012-05-18 Inst Substances Vegetales Utilisation de composes phenoliques pour la deglycation des proteines
ES2385160B1 (es) * 2010-12-23 2013-05-24 Italfármaco, S.A. Compuestos con actividad inhibitoria de factores de crecimiento de fibroblastos.
PT2777699T (pt) * 2012-02-02 2017-07-07 Invesfovea S L Dietilamina-2,5-di-hidroxibenzenossulfonato para o tratamento de degeneração macular relacionada com a idade
PL404138A1 (pl) * 2013-05-31 2014-12-08 Warszawski Uniwersytet Medyczny Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα
ES2759080T3 (es) * 2015-10-19 2020-05-07 Dobecure S L Administración local de etamsilato como medicamento

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115648A (en) * 1974-09-13 1978-09-19 Laboratorios Del Dr. Esteve, S.A. 2,5-Dihydroxy benzene sulfonic acid mono esters
US4513007A (en) * 1983-05-03 1985-04-23 Laboratoires Om Sa Method for treating heart disease
US4617311A (en) * 1985-05-17 1986-10-14 Eli Lilly And Company Antiasthmatic method
CH679372A5 (es) * 1989-04-07 1992-02-14 Vet Gerhard Stuker Dr Med
CH682716A5 (de) * 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5374772A (en) * 1992-12-08 1994-12-20 Hoffmann-Laroche Inc. Substituted benzoic acids, inhibitors of phospholipases A2
US5798356A (en) * 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
DE69814612T2 (de) * 1997-02-14 2004-03-11 Kissei Pharmaceutical Co., Ltd., Matsumoto Stoffe zur hemmung der bildung des pterygiums und seines postoperative wiederauftretens
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
EE200100342A (xx) * 1998-12-23 2002-10-15 Idea Ag Parendatud ravimvorm in vivo mitteinvasiivseks paikseks rakendamiseks
JP2000256259A (ja) * 1999-03-11 2000-09-19 Nippon Zoki Pharmaceut Co Ltd メイラード反応阻害剤
AU5871000A (en) * 1999-06-11 2001-01-02 Paul G. Abrams High dose radionuclide complexes for bone marrow suppression
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US20020037897A1 (en) * 2000-08-07 2002-03-28 3-Dimensional Pharmaceuticals, Inc. Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
JP2002193800A (ja) * 2000-12-22 2002-07-10 Taisho Pharmaceut Co Ltd Ｖｅｇｆ受容体拮抗剤
BR0207706A (pt) * 2001-02-28 2004-03-23 Melacure Therapeutics Ab ésteres de diaminoquinazolina para uso como inibidores da diidrofolato redutase
US7371777B2 (en) * 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
EP1429768B1 (de) * 2001-09-14 2016-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Neue arzneimittel zur inhalation
US7163958B2 (en) * 2002-07-03 2007-01-16 Nitromed Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
RU2002120366A (ru) * 2002-08-01 2005-02-27 БиоДием Лимитед (AU) Новые производные имидазолия и фармацевтические композиции на их основе
WO2004022551A1 (ja) * 2002-09-06 2004-03-18 Takeda Pharmaceutical Company Limited フランまたはチオフェン誘導体およびその医薬用途
ES2208123A1 (es) * 2002-11-29 2004-06-01 Laboratorios Del Dr. Esteve, S.A. Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento.
WO2004067009A1 (en) * 2003-01-29 2004-08-12 Dal-Hoon Son Pharmaceutical composition comprising an extract or compounds isolated from elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
AU2004263156B2 (en) * 2003-08-07 2009-02-26 Allergan, Inc. Method for treating cachexia with retinoid ligands
GB0321228D0 (en) * 2003-09-10 2003-10-08 Inpharmatica Ltd Modulating cell activity
AU2003303744A1 (en) * 2003-10-31 2005-06-17 Elan Pharma International Ltd. Novel nimesulide compositions
US20050222247A1 (en) * 2003-12-13 2005-10-06 Bayer Healthcare Ag Chroman derivatives
EP1836160A1 (en) * 2004-12-24 2007-09-26 CTG Pharma S.r.l. Compounds for treating metabolic syndrome
EP1676573A1 (en) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor
EP1749820A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Salts of substituted pyrazoline compounds, their preparation and use as medicaments
KR20080031936A (ko) * 2005-08-04 2008-04-11 노파르티스 아게 빌다글립틴의 염
CN100506804C (zh) * 2006-01-26 2009-07-01 于学敏 羟苯磺酸烷基吡嗪药物及其制备方法和应用
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
WO2007113855A1 (en) * 2006-03-30 2007-10-11 Council Of Scientific & Industrial Research A bioactive fraction from zingiber officinale and a process for the preparation thereof

Also Published As

Publication number Publication date
AR062396A1 (es) 2008-11-05
US20080114063A1 (en) 2008-05-15
CL2007002385A1 (es) 2008-01-18
AR062393A1 (es) 2008-11-05
PT2054045E (pt) 2011-08-31
WO2008020032A8 (en) 2008-04-17
EP2056804A1 (en) 2009-05-13
CL2007002386A1 (es) 2008-01-18
EP2056805A1 (en) 2009-05-13
US9060966B2 (en) 2015-06-23
PT2056805E (pt) 2011-09-02
ATE510536T1 (de) 2011-06-15
EP2056805B1 (en) 2011-05-25
CL2007002392A1 (es) 2008-01-18
WO2008020031A1 (en) 2008-02-21
WO2008020033A1 (en) 2008-02-21
ES2495965T3 (es) 2014-09-17
WO2008020034A1 (en) 2008-02-21
AR062390A1 (es) 2008-11-05
US20110152222A1 (en) 2011-06-23
PT2056804E (pt) 2014-07-11
ATE509621T1 (de) 2011-06-15
EP2054045A1 (en) 2009-05-06
AR062395A1 (es) 2008-11-05
WO2008020042A1 (en) 2008-02-21
CL2007002387A1 (es) 2008-01-18
EP2054045B1 (en) 2011-05-18
WO2008020032A1 (en) 2008-02-21
EP2056804B1 (en) 2013-05-22
CL2007002388A1 (es) 2008-01-18

Similar Documents

Publication Publication Date Title
AR062399A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de enfermedades de reaccion a tejido
AR062398A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar obesidad, hirsutismo, hipertricosis y verrugas viricas
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
AR067824A1 (es) Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer.
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
AR063097A1 (es) Pirazolopirimidinas[1,5-a] inhibidoras de quinasas dependientes de ciclina(cdk), composiciones farmaceuticas que las contienen y usos en el tratamiento de enfermedades proliferativas
AR102467A1 (es) Métodos para tratar infecciones por el virus filoviridae
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
PE20212303A1 (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
RU2007124329A (ru) ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ
AR063096A1 (es) Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
NO20090835L (no) Nye HIV-reverstranskriptaseinhibitorer
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
DOP2007000079A (es) Compuestos fenil amido heterocíclicos condensados
DOP2006000084A (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos
CL2004000590A1 (es) Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
AR067454A1 (es) Derivados de indano- amina, su preparacion y uso como medicamentos
SE0402925D0 (sv) Novel Compounds
AR063095A1 (es) Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina
AR022220A1 (es) Derivados de la imidazo[4,5-c]-piridin-4-ona, un procedimiento para su preparacion, el empleo de los mismos para preparar un medicamento, los medicamentosa base de estos compuestos, las composiciones farmaceuticas que contienen estos compuestos y un procedimiento para preparar estas composiciones fa

Legal Events

Date Code Title Description
FB Suspension of granting procedure